<DOC>
	<DOCNO>NCT00605618</DOCNO>
	<brief_summary>Part A : The purpose study find maximum tolerated dose BMS-777607 subject advance metastatic solid tumor Part B : The purpose study describe preliminary activity BMS-77607 subject advance metastatic gastroesophageal cancer , hormone refractory prostate cancer , head neck squamous cell carcinoma , type I papillary renal cell carcinoma</brief_summary>
	<brief_title>Multiple Ascending Dose Study BMS-777607 Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Part A : Subjects advance metastatic solid tumor either progressed standard therapy standard therapy know Part B : Subjects advance metastatic gastroesophageal cancer , HRPrC , HNSCC , PRCC either progressed standard therapy , standard therapy know . Eighteen ( 18 ) subject gastroesophageal cancer , HRPrC , HNSCC treat . Subjects PRCC ( 18 ) enrol feasible Tumor paraffin tissue block 610 unstained slide tumor tissue block must provide Subjects HRPrC must either measurable disease rise PSA level ( ≥3 consecutive rising level least 1 week interval PSA level ≥5 mg/ml ) . All subject must measurable disease assess CT MRI Know brain metastasis Uncontrolled significant cardiovascular disease Retinal atrophy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>